Kumar Neil 13D and 13G filings for BridgeBio Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-16 7:15 pm Purchase | 2023-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | Kumar Neil | 9,959,504 5.590% | 135,596 (+1.38%) | Filing |
| 2023-02-14 4:18 pm Purchase | 2022-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | Kumar Neil | 9,823,908 6.420% | 820,697 (+9.12%) | Filing |
| 2022-02-14 4:50 pm Purchase | 2021-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | Kumar Neil | 9,003,211 6.050% | 672,614 (+8.07%) | Filing |
| 2021-02-16 5:02 pm Sale | 2020-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | Kumar Neil | 8,330,597 6.740% | -288,186 (-3.34%) | Filing |
| 2020-02-14 4:00 pm Purchase | 2019-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | Kumar Neil | 8,618,783 6.980% | 8,618,783 (New Position) | Filing |